# Reviewed PTCy meta-analysis results with new RRM and BK endpoints, decomposed OS into NRM/RRM components (RRM drives OS benefit), and investigated GVL preservation finding that aGVHD reduction co-occurs with RRM reduction suggesting GVL-GVHD dissociation.

## User

Review Table2_post_block9.csv results. This was a re-analysis after extracting 2 addtitional endpoints from studies- relapse related mortality and BK virus or hemorrhagic cystitis

## Assistant



<div><thinking id="thinking-1780154428961-no02o">
Let me read the full CSV file to review the results.
</thinking><span data-thinking-duration-ms="1605"></span></div>



<div><tool-call id="toolu_01QuQzAMhyDRgJ8CWngndCDj"><script type="application/json">{"version":1,"name":"read","input":{"file_path":"03_models/post_block9/Table2_post_block9.csv"},"caption":"03_models/post_block9/Table2_post_block9.csv","captionLink":"03_models/post_block9/Table2_post_block9.csv"}</script></tool-call></div>

<div><tool-result call-id="toolu_01QuQzAMhyDRgJ8CWngndCDj"><script type="application/json">{"version":1,"status":"success","result":{"type":"text","value":"[File: 2.3KB, 26 lines, showing lines 1-26]\n     1→slug,model,k,n_total,or_median,ci_low,c...[truncated, total 2569 chars]"},"resultPreview":{"type":"code","value":"[File: 2.3KB, 26 lines, showing lines 1-26]\nslug,model,k,n_total,or_median,ci_low,ci_high,tau\nc1_os,m1,40,19724,0.7877179355110338,0.7278030059014194,0.8530020117300631,0.6142327385858005\nc1_os,m2_steroid,40,19724,0.8567908521284862,0.7654213548756396,0.9562784368707613,0.5845895305361467\nc1_nrm,m1,12,1309,0.8830511071046998,0.661144496089341,1.1773259374839282,0.7203849451396538\nc1_nrm,m2_steroid,12,1309,0.9007641476298258,0.5881321206507246,1.3587122725550331,0.5983083515721015\nc1_agvhd,m1,28,4197,0.6749796761752712,0.5865728311695977,0.7784356744884737,0.679528596739718\nc1_cmv,m1,22,3328,1.2578891395587635,1.0745523467876987,1.469064530064831,0.7447143963349268\nc1_cmv,m2_steroid,22,3328,1.2474184125513734,1.0101613015223445,1.535433015926604,0.763932377396484\nc1_bsi,m1,6,806,1.869926999247667,1.3269969913897732,2.623297620830629,0.9583886212549938\nc1_ifi_any,m1,6,2243,0.4338381923132795,0.2929042780782665,0.6334625856629813,1.6361693731380949\nc2_os,m1,10,12851,0.8146149113457113,0.7361756509529209,0.9023905506960838,0.5140116108166697\nc2_os,m2_steroid,10,12851,0.8160196910551548,0.7069856208377358,0.9385242165787079,0.6975691562020517\nc2_agvhd,m1,9,1099,0.5819940153590194,0.4412755120654564,0.7669692021592837,0.5472239763897001\nc2_cmv,m1,13,1571,0.915028158033013,0.726181091454994,1.14975187192482,0.6399203326117908\nc2_cmv,m2_steroid,13,1571,0.9823937298035857,0.7783804887188076,1.2439838578192912,0.7384907141218444\nc3_os,m1,6,4746,1.1140036653881114,0.9537280977296823,1.3014923495902728,0.9218963850745197\nc3_nrm,m1,5,2529,0.9622738549170925,0.7443240255534153,1.2411305087295503,1.221518393629396\nc3_agvhd,m1,7,2450,1.0038770966058825,0.8016508678543526,1.2546476216166558,0.8239248599956768\nc3_cgvhd,m1,4,383,0.6689559334348173,0.39306427271671784,1.1372426174677417,0.41455176824185946\nc1_rrm,m1,38,19225,0.8436084694193037,0.7621852614983622,0.9329441949399245,0.45278474869247937\nc1_rrm,m2_steroid,38,19225,0.8266979610408982,0.7308492217402224,0.9338882891380597,0.5201860518809828\nc2_rrm,m1,10,17182,0.7869556812023294,0.6915387289864219,0.8914603190629808,0.16354075586036665\nc3_rrm,m1,6,692,0.7974965983790036,0.49633164335152663,1.2675891552115381,0.3949255393906881\nc1_bk,m1,11,1333,2.4756792034173474,1.8229454299877592,3.384506718314485,1.0589533403892797\nc2_bk,m1,3,313,2.435991836865141,1.3962144077759981,4.259331279047919,0.5683143780693538\n"},"elapsedMs":76}</script></tool-result></div>



<div><tool-call id="toolu_01WBH6m2Sqm4Wq1vnq9GBM3R"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"library(tidyverse)\n\ntbl <- read_csv(\"03_models/post_block9/Table2_post_block9.csv\")\n\ntbl |...[truncated, total 346 chars]","intent":"Format and review Table2 results"},"intent":"Format and review Table2 results","inputPreview":{"type":"code","value":"library(tidyverse)\n\ntbl <- read_csv(\"03_models/post_block9/Table2_post_block9.csv\")\n\ntbl |>\n  mutate(\n    across(c(or_median, ci_low, ci_high, tau), ~round(., 2)),\n    sig = case_when(\n      ci_high < 1 ~ \"lower\",\n      ci_low > 1 ~ \"higher\",\n      TRUE ~ \"ns\"\n    )\n  ) |>\n  select(slug, model, k, n_total, or_median, ci_low, ci_high, tau, sig)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01WBH6m2Sqm4Wq1vnq9GBM3R"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n── Attaching core tidyverse packages ─────────────── tidyverse 2.0.0 ──\n✔ forcats ...[truncated, total 1864 chars]"}]},"resultPreview":{"type":"code","value":"── Attaching core tidyverse packages ─────────────── tidyverse 2.0.0 ──\n✔ forcats   1.0.1     ✔ purrr     1.2.2\n✔ ggplot2   4.0.3     ✔ stringr   1.6.0\n✔ lubridate 1.9.5     ✔ tibble    3.3.1\n── Conflicts ───────────────────────────────── tidyverse_conflicts() ──\n✖ dplyr::filter() masks stats::filter()\n✖ dplyr::lag()    masks stats::lag()\nℹ Use the conflicted package to force all conflicts to become errors\n\rindexing Table2_post_block9.csv [================] 578.07MB/s, eta:  0s\r                                                                       \rRows: 24 Columns: 8\n── Column specification ───────────────────────────────────────────────\nDelimiter: \",\"\nchr (2): slug, model\ndbl (6): k, n_total, or_median, ci_low, ci_high, tau\n\nℹ Use `spec()` to retrieve the full column specification for this data.\nℹ Specify the column types or set `show_col_types = FALSE` to quiet this message.\n# A tibble: 24 × 9\n   slug       model      k n_total or_median ci_low ci_high   tau sig  \n   <chr>      <chr>  <dbl>   <dbl>     <dbl>  <dbl>   <dbl> <dbl> <chr>\n 1 c1_os      m1        40   19724      0.79   0.73    0.85  0.61 lower\n 2 c1_os      m2_st…    40   19724      0.86   0.77    0.96  0.58 lower\n 3 c1_nrm     m1        12    1309      0.88   0.66    1.18  0.72 ns   \n 4 c1_nrm     m2_st…    12    1309      0.9    0.59    1.36  0.6  ns   \n 5 c1_agvhd   m1        28    4197      0.67   0.59    0.78  0.68 lower\n 6 c1_cmv     m1        22    3328      1.26   1.07    1.47  0.74 high…\n 7 c1_cmv     m2_st…    22    3328      1.25   1.01    1.54  0.76 high…\n 8 c1_bsi     m1         6     806      1.87   1.33    2.62  0.96 high…\n 9 c1_ifi_any m1         6    2243      0.43   0.29    0.63  1.64 lower\n10 c2_os      m1        10   12851      0.81   0.74    0.9   0.51 lower\n# ℹ 14 more rows\n# ℹ Use `print(n = ...)` to see more rows"},"elapsedMs":345}</script></tool-result></div>



<div><tool-call id="toolu_01TWFXthLQABA69fdvN1YfHc"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"tbl |>\n  mutate(\n    across(c(or_median, ci_low, ci_high, tau), ~round(., 2)),\n    sig = c...[truncated, total 280 chars]","intent":"Print all rows"},"intent":"Print all rows","inputPreview":{"type":"code","value":"tbl |>\n  mutate(\n    across(c(or_median, ci_low, ci_high, tau), ~round(., 2)),\n    sig = case_when(\n      ci_high < 1 ~ \"lower\",\n      ci_low > 1 ~ \"higher\",\n      TRUE ~ \"ns\"\n    )\n  ) |>\n  select(slug, model, k, n_total, or_median, ci_low, ci_high, tau, sig) |>\n  print(n = 30)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01TWFXthLQABA69fdvN1YfHc"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n# A tibble: 24 × 9\n   slug       model      k n_total or_median ci_low ci_high   t...[truncated, total 1921 chars]"}]},"resultPreview":{"type":"code","value":"# A tibble: 24 × 9\n   slug       model      k n_total or_median ci_low ci_high   tau sig  \n   <chr>      <chr>  <dbl>   <dbl>     <dbl>  <dbl>   <dbl> <dbl> <chr>\n 1 c1_os      m1        40   19724      0.79   0.73    0.85  0.61 lower\n 2 c1_os      m2_st…    40   19724      0.86   0.77    0.96  0.58 lower\n 3 c1_nrm     m1        12    1309      0.88   0.66    1.18  0.72 ns   \n 4 c1_nrm     m2_st…    12    1309      0.9    0.59    1.36  0.6  ns   \n 5 c1_agvhd   m1        28    4197      0.67   0.59    0.78  0.68 lower\n 6 c1_cmv     m1        22    3328      1.26   1.07    1.47  0.74 high…\n 7 c1_cmv     m2_st…    22    3328      1.25   1.01    1.54  0.76 high…\n 8 c1_bsi     m1         6     806      1.87   1.33    2.62  0.96 high…\n 9 c1_ifi_any m1         6    2243      0.43   0.29    0.63  1.64 lower\n10 c2_os      m1        10   12851      0.81   0.74    0.9   0.51 lower\n11 c2_os      m2_st…    10   12851      0.82   0.71    0.94  0.7  lower\n12 c2_agvhd   m1         9    1099      0.58   0.44    0.77  0.55 lower\n13 c2_cmv     m1        13    1571      0.92   0.73    1.15  0.64 ns   \n14 c2_cmv     m2_st…    13    1571      0.98   0.78    1.24  0.74 ns   \n15 c3_os      m1         6    4746      1.11   0.95    1.3   0.92 ns   \n16 c3_nrm     m1         5    2529      0.96   0.74    1.24  1.22 ns   \n17 c3_agvhd   m1         7    2450      1      0.8     1.25  0.82 ns   \n18 c3_cgvhd   m1         4     383      0.67   0.39    1.14  0.41 ns   \n19 c1_rrm     m1        38   19225      0.84   0.76    0.93  0.45 lower\n20 c1_rrm     m2_st…    38   19225      0.83   0.73    0.93  0.52 lower\n21 c2_rrm     m1        10   17182      0.79   0.69    0.89  0.16 lower\n22 c3_rrm     m1         6     692      0.8    0.5     1.27  0.39 ns   \n23 c1_bk      m1        11    1333      2.48   1.82    3.38  1.06 high…\n24 c2_bk      m1         3     313      2.44   1.4     4.26  0.57 high…"},"elapsedMs":128}</script></tool-result></div>



<div><thinking id="thinking-1780154444037-pcqje">


<span class="thinking-topic">Reviewing new endpoints: RRM and BK</span>



Let me summarize the new endpoints (relapse-related mortality = rrm, and BK virus/hemorrhagic cystitis = bk) and compare them with the existing results.
</thinking><span data-thinking-duration-ms="1517"></span></div>

MEMO: 2 tool calls. This is exploratory review, summarizing what I see.

Here's a summary of the re-analysis with the two new endpoints (**relapse-related mortality** and **BK virus/hemorrhagic cystitis**):

### New endpoints

**Relapse-related mortality (RRM)** — PTCy is associated with significantly lower RRM:

| Comparison | Model | k | OR (95% CI) | τ |
|---|---|---|---|---|
| c1 (all) | m1 | 38 | 0.84 (0.76–0.93) | 0.45 |
| c1 (all) | m2_steroid | 38 | 0.83 (0.73–0.93) | 0.52 |
| c2 (paired) | m1 | 10 | 0.79 (0.69–0.89) | 0.16 |
| c3 (MSD) | m1 | 6 | 0.80 (0.50–1.27) | 0.39 |

The c1 and c2 results are significant. The c2 estimate has notably low heterogeneity (τ = 0.16). The c3 comparison is underpowered (k = 6, wide CI).

**BK virus / hemorrhagic cystitis** — PTCy is associated with substantially higher risk:

| Comparison | Model | k | OR (95% CI) | τ |
|---|---|---|---|---|
| c1 (all) | m1 | 11 | 2.48 (1.82–3.38) | 1.06 |
| c2 (paired) | m1 | 3 | 2.44 (1.40–4.26) | 0.57 |

Both are significant with large effect sizes (~2.5x odds). The c2 estimate is based on only 3 studies but directionally consistent. This is the largest adverse signal in the table, comparable in magnitude to BSI (OR 1.87).

### Consistency with prior results

The existing endpoints appear unchanged — OS, aGVHD, CMV, BSI, IFI, and NRM estimates match the patterns from before. The addition of 2 more studies to the RRM endpoint (k = 38 vs. the 40 for OS) suggests most of the OS studies also reported RRM.

### Key takeaways

- The RRM finding strengthens the PTCy efficacy narrative: not only is OS better, but relapse-related deaths are specifically reduced. This is notable because NRM alone was not significant.
- The BK/HC finding is a clear safety concern and the strongest adverse association after BSI and CMV. The high τ in c1 (1.06) suggests substantial between-study variability.

I'll suggest some questions below.


<span class="suggestion">Compare the magnitude and direction of all endpoints in a single forest-style summary plot.</span>


<span class="suggestion">Examine whether the BK virus studies overlap with the BSI studies — are these correlated adverse events?</span>


<span class="suggestion">Check how the RRM result relates to OS and NRM (e.g., does OS improvement decompose into RRM vs. NRM components?).</span>





## User

Check how the RRM result relates to OS and NRM (e.g., does OS improvement decompose into RRM vs. NRM components?).

## Assistant



<div><tool-call id="toolu_01SyKp6EUsMjqbx6gu2SZu2w"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"tbl <- read_csv(\"03_models/post_block9/Table2_post_block9.csv\", show_col_types = FALSE)\n\n#...[truncated, total 560 chars]","intent":"Compare OS, NRM, and RRM across comparisons"},"intent":"Compare OS, NRM, and RRM across comparisons","inputPreview":{"type":"code","value":"tbl <- read_csv(\"03_models/post_block9/Table2_post_block9.csv\", show_col_types = FALSE)\n\n# Focus on c1 m1 results for OS, NRM, and RRM\ndecomp <- tbl |>\n  filter(model == \"m1\", slug %in% c(\"c1_os\", \"c1_nrm\", \"c1_rrm\", \"c2_os\", \"c2_nrm\", \"c2_rrm\", \"c3_os\", \"c3_nrm\", \"c3_rrm\")) |>\n  mutate(\n    comparison = str_extract(slug, \"^c\\\\d\"),\n    endpoint = str_extract(slug, \"(?<=_).+\"),\n    across(c(or_median, ci_low, ci_high), ~round(., 3))\n  ) |>\n  select(comparison, endpoint, k, n_total, or_median, ci_low, ci_high, tau)\n\ndecomp |> arrange(comparison, endpoint)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01SyKp6EUsMjqbx6gu2SZu2w"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n\rindexing Table2_post_block9.csv [================] 578.07MB/s, eta:  0s\r         ...[truncated, total 863 chars]"}]},"resultPreview":{"type":"code","value":"indexing Table2_post_block9.csv [================] 578.07MB/s, eta:  0s\r                                                                       \r# A tibble: 8 × 8\n  comparison endpoint     k n_total or_median ci_low ci_high   tau\n  <chr>      <chr>    <dbl>   <dbl>     <dbl>  <dbl>   <dbl> <dbl>\n1 c1         nrm         12    1309     0.883  0.661   1.18  0.720\n2 c1         os          40   19724     0.788  0.728   0.853 0.614\n3 c1         rrm         38   19225     0.844  0.762   0.933 0.453\n4 c2         os          10   12851     0.815  0.736   0.902 0.514\n5 c2         rrm         10   17182     0.787  0.692   0.891 0.164\n6 c3         nrm          5    2529     0.962  0.744   1.24  1.22 \n7 c3         os           6    4746     1.11   0.954   1.30  0.922\n8 c3         rrm          6     692     0.797  0.496   1.27  0.395"},"elapsedMs":142}</script></tool-result></div>



<div><tool-call id="toolu_01MRpCHhmiExuD5rxAR1v9KZ"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"library(ggplot2)\n\nplot_df <- decomp |>\n  mutate(\n    endpoint = factor(endpoint, levels = ...[truncated, total 703 chars]","intent":"Forest-style plot comparing OS, NRM, and RRM"},"intent":"Forest-style plot comparing OS, NRM, and RRM","inputPreview":{"type":"code","value":"library(ggplot2)\n\nplot_df <- decomp |>\n  mutate(\n    endpoint = factor(endpoint, levels = c(\"os\", \"nrm\", \"rrm\"),\n                      labels = c(\"Overall Survival\", \"Non-Relapse Mortality\", \"Relapse-Related Mortality\")),\n    comparison = factor(comparison, levels = c(\"c1\", \"c2\", \"c3\"),\n                        labels = c(\"C1: All studies\", \"C2: Paired\", \"C3: MSD\"))\n  )\n\nggplot(plot_df, aes(x = or_median, y = endpoint)) +\n  geom_vline(xintercept = 1, linetype = \"dashed\", color = \"grey50\") +\n  geom_pointrange(aes(xmin = ci_low, xmax = ci_high)) +\n  facet_wrap(~comparison, ncol = 1) +\n  scale_x_log10() +\n  labs(x = \"Odds Ratio (log scale)\", y = NULL,\n       title = \"OS decomposition: NRM vs RRM\")\n","language":"r"}}</script></tool-call></div>

<tool-image call-id="toolu_01MRpCHhmiExuD5rxAR1v9KZ" src="8e09e9e381a744655a577fdcfe90b42c277cbd81.png" width="672" height="672"></tool-image>



<div><tool-result call-id="toolu_01MRpCHhmiExuD5rxAR1v9KZ"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Execution time: 228ms"},{"type":"image-data","data":"iVBORw0KGgoAAAANSUhEUgAAAqAAAAKgCAYAAABEPM/FAAC5PUlEQVR4AezBd3zNh/748df55GQPIo3ElsRIjVC7ah...[truncated, total 63304 chars]","mediaType":"image/png"}]},"resultPreview":{"type":"code","value":""},"elapsedMs":347}</script></tool-result></div>



The plot tells a clear story about where the OS benefit comes from.

**C1 (all studies):** OS improvement (OR 0.79) appears to be driven primarily by **reduced relapse-related mortality** (OR 0.84, significant) rather than NRM (OR 0.88, non-significant with wide CI). Note that NRM is estimated from only 12 studies (n = 1,309) versus 38 for RRM (n = 19,225), so NRM is severely underpowered — we can't confidently say NRM doesn't contribute, only that the evidence is much stronger for RRM.

**C2 (paired):** NRM was not estimable here (no row), but RRM is significant (OR 0.79) and tracks closely with OS (OR 0.81). The very low heterogeneity on RRM (τ = 0.16) is notable — the RRM benefit is consistent across studies.

**C3 (MSD):** Neither component is significant, consistent with the non-significant OS result in this subgroup.

The key interpretation: the OS advantage of PTCy appears to decompose primarily into a **relapse-related mortality benefit**. The NRM data are too sparse to draw strong conclusions, but the point estimates suggest a modest, non-significant reduction. This is somewhat surprising — you might expect a GvHD-reducing regimen to show its mortality benefit through NRM, but the signal is in RRM instead.

I'll suggest some questions below.


<span class="suggestion">Investigate whether the RRM benefit might be mediated by the graft-versus-leukemia effect preservation or relapse rate differences.</span>


<span class="suggestion">Check whether the studies reporting NRM overlap with the RRM studies, and why so few report NRM.</span>


<span class="suggestion">Add the steroid-adjusted (m2) estimates to this decomposition plot for a fuller picture.</span>





## User

Investigate whether the RRM benefit might be mediated by the graft-versus-leukemia effect preservation or relapse rate differences.

## Assistant



<div><thinking id="thinking-1780158201338-0mwex">


<span class="thinking-topic">Checking available data for relapse rates</span>



The user wants to understand whether PTCy's RRM benefit comes from lower relapse rates or from better outcomes once relapse occurs (GVL preservation). I need to check if relapse rate data is available in the outcomes dataset.
</thinking><span data-thinking-duration-ms="3871"></span></div>



<div><tool-call id="toolu_01TZkgR2C75S56nr31atHGLK"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"# Check what endpoints are available in the outcomes data\noutcomes |> distinct(slug) |> pull()\n","intent":"Check if relapse rate endpoint exists in outcomes data"},"intent":"Check if relapse rate endpoint exists in outcomes data","inputPreview":{"type":"code","value":"# Check what endpoints are available in the outcomes data\noutcomes |> distinct(slug) |> pull()\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01TZkgR2C75S56nr31atHGLK"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\nError: Must use existing variables.\n✖ `slug` not found in `.data`.\n\n\nExecution time: 32ms"}]},"resultPreview":{"type":"code","value":"Error: Must use existing variables.\n✖ `slug` not found in `.data`."},"elapsedMs":118}</script></tool-result></div>



<div><tool-call id="toolu_01YPN31ssSANTqy6woyV1S6T"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"names(outcomes)\n","intent":"Check column names in outcomes"},"intent":"Check column names in outcomes","inputPreview":{"type":"code","value":"names(outcomes)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01YPN31ssSANTqy6woyV1S6T"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n [1] \"outcome_id\"                   \"arm_id\"                      \n [3] \"study_id\"...[truncated, total 1168 chars]"}]},"resultPreview":{"type":"code","value":"[1] \"outcome_id\"                   \"arm_id\"                      \n [3] \"study_id\"                     \"cohort_id\"                   \n [5] \"outcome_category\"             \"outcome_subtype\"             \n [7] \"timepoint\"                    \"timepoint_days_numeric\"      \n [9] \"is_primary_timepoint\"         \"is_primary_definition\"       \n[11] \"denominator_n\"                \"event_count\"                 \n[13] \"proportion_reported_pct\"      \"cumulative_incidence_pct\"    \n[15] \"ci_lower_pct\"                 \"ci_upper_pct\"                \n[17] \"ci_method\"                    \"competing_risks_handled\"     \n[19] \"hr_value\"                     \"hr_ci_lower\"                 \n[21] \"hr_ci_upper\"                  \"hr_comparator_arm_id\"        \n[23] \"hr_adjusted\"                  \"incidence_rate_value\"        \n[25] \"incidence_rate_unit\"          \"person_time_total\"           \n[27] \"person_time_unit\"             \"median_time_to_event_days\"   \n[29] \"ascertainment_method\"         \"screening_frequency_per_week\"\n[31] \"definition_text\"              \"data_source\"                 \n[33] \"data_quality_flag\"            \"extraction_notes\""},"elapsedMs":109}</script></tool-result></div>



<div><tool-call id="toolu_01FVdXH718eTM649DAC2UuPL"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"outcomes |> distinct(outcome_category) |> pull()\n","intent":"Check available outcome categories"},"intent":"Check available outcome categories","inputPreview":{"type":"code","value":"outcomes |> distinct(outcome_category) |> pull()\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01FVdXH718eTM649DAC2UuPL"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n [1] \"CMV\"                          \"NRM\"                         \n [3] \"aGVHD\"   ...[truncated, total 534 chars]"}]},"resultPreview":{"type":"code","value":"[1] \"CMV\"                          \"NRM\"                         \n [3] \"aGVHD\"                        \"cGVHD\"                       \n [5] \"overall_mortality\"            \"infection_related_mortality\" \n [7] \"engraftment_failure\"          \"other_infection\"             \n [9] \"BSI\"                          \"second_line_GVHD_therapy_use\"\n[11] \"IFI_any\"                      \"steroid_refractory_aGVHD\"    \n[13] \"IFI_yeast\"                    \"IFI_mold\"                    \n[15] \"relapse_related_mortality\""},"elapsedMs":90}</script></tool-result></div>



<div><tool-call id="toolu_0146azE7MAHEtGTTXvXMXyrH"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"# No relapse rate endpoint - check what's in the arms data\nnames(arms)\n","intent":"Check arms data for relapse info"},"intent":"Check arms data for relapse info","inputPreview":{"type":"code","value":"# No relapse rate endpoint - check what's in the arms data\nnames(arms)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_0146azE7MAHEtGTTXvXMXyrH"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n [1] \"arm_id\"                                \n [2] \"study_id\"                     ...[truncated, total 4307 chars]"}]},"resultPreview":{"type":"code","value":"[1] \"arm_id\"                                \n [2] \"study_id\"                              \n [3] \"arm_label_in_paper\"                    \n [4] \"arm_role\"                              \n [5] \"comparison_1_eligible\"                 \n [6] \"comparison_2_eligible\"                 \n [7] \"comparison_3_eligible\"                 \n [8] \"n_patients\"                            \n [9] \"pct_male\"                              \n[10] \"age_median_years\"                      \n[11] \"age_iqr_low\"                           \n[12] \"age_iqr_high\"                          \n[13] \"age_range_min\"                         \n[14] \"age_range_max\"                         \n[15] \"age_mean_years\"                        \n[16] \"age_sd_years\"                          \n[17] \"disease_aml_pct\"                       \n[18] \"disease_all_pct\"                       \n[19] \"disease_mds_pct\"                       \n[20] \"disease_mpn_pct\"                       \n[21] \"disease_cml_pct\"                       \n[22] \"disease_lymphoma_pct\"                  \n[23] \"disease_mm_pct\"                        \n[24] \"disease_cll_pct\"                       \n[25] \"disease_saa_pct\"                       \n[26] \"disease_other_pct\"                     \n[27] \"disease_risk_high_pct\"                 \n[28] \"disease_risk_intermediate_pct\"         \n[29] \"disease_risk_low_pct\"                  \n[30] \"disease_risk_classifier_used\"          \n[31] \"donor_msd_pct\"                         \n[32] \"donor_mud_pct\"                         \n[33] \"donor_mmud_pct\"                        \n[34] \"donor_haplo_pct\"                       \n[35] \"donor_ucb_pct\"                         \n[36] \"donor_predominant\"                     \n[37] \"graft_pbsc_pct\"                        \n[38] \"graft_bm_pct\"                          \n[39] \"graft_ucb_pct\"                         \n[40] \"graft_predominant\"                     \n[41] \"conditioning_mac_pct\"                  \n[42] \"conditioning_ric_pct\"                  \n[43] \"conditioning_nma_pct\"                  \n[44] \"conditioning_classification_scheme\"    \n[45] \"conditioning_predominant\"              \n[46] \"tbi_used_pct\"                          \n[47] \"hla_10_10_pct\"                         \n[48] \"hla_9_10_pct\"                          \n[49] \"hla_8_10_or_lower_pct\"                 \n[50] \"hla_haplo_pct\"                         \n[51] \"cmv_recipient_pos_pct\"                 \n[52] \"cmv_donor_pos_pct\"                     \n[53] \"cmv_DposRpos_pct\"                      \n[54] \"cmv_DposRneg_pct\"                      \n[55] \"cmv_DnegRpos_pct\"                      \n[56] \"cmv_DnegRneg_pct\"                      \n[57] \"cmv_serostatus_reporting\"              \n[58] \"ptcy_used\"                             \n[59] \"ptcy_dose_mg_kg_per_dose\"              \n[60] \"ptcy_n_doses\"                          \n[61] \"ptcy_days_post_transplant\"             \n[62] \"ptcy_total_dose_mg_kg\"                 \n[63] \"ptcy_dose_category\"                    \n[64] \"cni_used\"                              \n[65] \"cni_agent\"                             \n[66] \"cni_target_trough_ng_ml_range\"         \n[67] \"mmf_used\"                              \n[68] \"mmf_total_daily_dose_mg\"               \n[69] \"mtx_used\"                              \n[70] \"mtx_schedule\"                          \n[71] \"mtx_total_dose_mg_m2\"                  \n[72] \"sirolimus_used\"                        \n[73] \"abatacept_used\"                        \n[74] \"other_immunosuppressant_used\"          \n[75] \"other_immunosuppressant_description\"   \n[76] \"atg_used\"                              \n[77] \"atg_agent\"                             \n[78] \"atg_total_dose_mg_kg\"                  \n[79] \"atg_dose_category\"                     \n[80] \"atg_timing\"                            \n[81] \"letermovir_use\"                        \n[82] \"letermovir_era_proxy\"                  \n[83] \"antifungal_prophylaxis_agent\"          \n[84] \"antifungal_mold_active\"                \n[85] \"antifungal_duration_target\"            \n[86] \"antibacterial_prophylaxis_agent\"       \n[87] \"pjp_prophylaxis_agent\"                 \n[88] \"cmv_monitoring_method\"                 \n[89] \"cmv_monitoring_frequency_per_week\"     \n[90] \"cmv_preemptive_threshold\"              \n[91] \"systemic_steroid_for_gvhd_exposure_pct\"\n[92] \"steroid_exposure_duration_days_median\" \n[93] \"second_line_gvhd_therapy_exposure_pct\""},"elapsedMs":76}</script></tool-result></div>



<div><thinking id="thinking-1780158216887-a8hdo">


<span class="thinking-topic">Assessing data availability for relapse rates</span>



There's no relapse rate endpoint in the extracted outcomes. I only have relapse-related mortality (RRM), not relapse incidence itself. Without relapse rates, I can't directly decompose whether the RRM benefit comes from fewer relapses vs. better post-relapse survival. But I can reason about it using available data.



<span class="thinking-topic">Considering indirect evidence from disease risk and other covariates</span>



Let me check if disease risk distributions differ between PTCy and non-PTCy arms, and look at what we can infer indirectly.
</thinking><span data-thinking-duration-ms="6105"></span></div>



<div><tool-call id="toolu_01B6NP9pohSJMK6wXN4KqxT6"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"# Check if relapse rate was extracted as a separate endpoint\noutcomes |> \n  filter(str_det...[truncated, total 177 chars]","intent":"Check for relapse incidence data"},"intent":"Check for relapse incidence data","inputPreview":{"type":"code","value":"# Check if relapse rate was extracted as a separate endpoint\noutcomes |> \n  filter(str_detect(outcome_category, \"[Rr]elapse\")) |> \n  distinct(outcome_category, outcome_subtype)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01B6NP9pohSJMK6wXN4KqxT6"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n# A tibble: 1 × 2\n  outcome_category          outcome_subtype      \n  <chr>       ...[truncated, total 197 chars]"}]},"resultPreview":{"type":"code","value":"# A tibble: 1 × 2\n  outcome_category          outcome_subtype      \n  <chr>                     <chr>                \n1 relapse_related_mortality RRM_any_cause_relapse"},"elapsedMs":97}</script></tool-result></div>



<div><tool-call id="toolu_019jop15DXLbAoES1cvF3y8M"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"# Compare disease risk profiles between PTCy and non-PTCy arms\narms |>\n  mutate(group = if...[truncated, total 551 chars]","intent":"Compare disease risk and transplant characteristics between groups"},"intent":"Compare disease risk and transplant characteristics between groups","inputPreview":{"type":"code","value":"# Compare disease risk profiles between PTCy and non-PTCy arms\narms |>\n  mutate(group = if_else(ptcy_used, \"PTCy\", \"Non-PTCy\")) |>\n  group_by(group) |>\n  summarise(\n    n_arms = n(),\n    high_risk_median = median(disease_risk_high_pct, na.rm = TRUE),\n    high_risk_mean = mean(disease_risk_high_pct, na.rm = TRUE),\n    n_risk_reported = sum(!is.na(disease_risk_high_pct)),\n    aml_median = median(disease_aml_pct, na.rm = TRUE),\n    haplo_median = median(donor_haplo_pct, na.rm = TRUE),\n    mac_median = median(conditioning_mac_pct, na.rm = TRUE)\n  )\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_019jop15DXLbAoES1cvF3y8M"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\nError: ℹ In argument: `group = if_else(ptcy_used, \"PTCy\",\n  \"Non-PTCy\")`.\nCaused b...[truncated, total 200 chars]"}]},"resultPreview":{"type":"code","value":"Error: ℹ In argument: `group = if_else(ptcy_used, \"PTCy\",\n  \"Non-PTCy\")`.\nCaused by error in `if_else()`:\n! `condition` must be a logical vector, not a character vector."},"elapsedMs":125}</script></tool-result></div>



<div><tool-call id="toolu_018TXn3NLkCbWXctLwZhBa1L"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"arms |> count(ptcy_used) |> head()\n","intent":"Check ptcy_used values"},"intent":"Check ptcy_used values","inputPreview":{"type":"code","value":"arms |> count(ptcy_used) |> head()\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_018TXn3NLkCbWXctLwZhBa1L"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n# A tibble: 3 × 2\n  ptcy_used     n\n  <chr>     <int>\n1 N           225\n2 Y       ...[truncated, total 137 chars]"}]},"resultPreview":{"type":"code","value":"# A tibble: 3 × 2\n  ptcy_used     n\n  <chr>     <int>\n1 N           225\n2 Y           279\n3 mixed        21"},"elapsedMs":103}</script></tool-result></div>



<div><tool-call id="toolu_01C9vCdXvgkKFgFzTU8ZkLDY"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"arms |>\n  filter(ptcy_used %in% c(\"Y\", \"N\")) |>\n  mutate(group = if_else(ptcy_used == \"Y\",...[truncated, total 499 chars]","intent":"Compare disease and transplant characteristics"},"intent":"Compare disease and transplant characteristics","inputPreview":{"type":"code","value":"arms |>\n  filter(ptcy_used %in% c(\"Y\", \"N\")) |>\n  mutate(group = if_else(ptcy_used == \"Y\", \"PTCy\", \"Non-PTCy\")) |>\n  group_by(group) |>\n  summarise(\n    n_arms = n(),\n    high_risk_pct = median(disease_risk_high_pct, na.rm = TRUE),\n    n_risk = sum(!is.na(disease_risk_high_pct)),\n    aml_pct = median(disease_aml_pct, na.rm = TRUE),\n    haplo_pct = median(donor_haplo_pct, na.rm = TRUE),\n    mac_pct = median(conditioning_mac_pct, na.rm = TRUE),\n    bm_pct = median(graft_bm_pct, na.rm = TRUE)\n  )\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_01C9vCdXvgkKFgFzTU8ZkLDY"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n# A tibble: 2 × 8\n  group    n_arms high_risk_pct n_risk aml_pct haplo_pct mac_pct...[truncated, total 336 chars]"}]},"resultPreview":{"type":"code","value":"# A tibble: 2 × 8\n  group    n_arms high_risk_pct n_risk aml_pct haplo_pct mac_pct bm_pct\n  <chr>     <int> <chr>          <int> <chr>   <chr>     <chr>   <chr> \n1 Non-PTCy    225 57               223 48.3    0         44.9    2.2   \n2 PTCy        279 50.9             277 49      100       43.2    23"},"elapsedMs":94}</script></tool-result></div>



<div><thinking id="thinking-1780158241102-jvl0w">


<span class="thinking-topic">Interpreting disease risk and graft characteristics</span>



Interesting - PTCy arms actually have slightly *lower* high-risk disease (50.9% vs 57%) despite having overwhelmingly haploidentical donors (100% vs 0% median). And BM graft source is much higher in PTCy (23% vs 2.2%).

Let me also check if there's aGVHD data that might speak to GVL preservation - lower GVHD but similar/better RRM could suggest GVL is preserved despite less GVHD.
</thinking><span data-thinking-duration-ms="15282"></span></div>



<div><tool-call id="toolu_011ZsKMuwF2ox4zkAuJMegQj"><script type="application/json">{"version":1,"name":"executeCode","input":{"code":"# Look at the key comparison: aGVHD is reduced but RRM is also reduced\n# This pattern sugg...[truncated, total 630 chars]","intent":"Side-by-side view of aGVHD and RRM results"},"intent":"Side-by-side view of aGVHD and RRM results","inputPreview":{"type":"code","value":"# Look at the key comparison: aGVHD is reduced but RRM is also reduced\n# This pattern suggests GVL is preserved despite less GVHD\ntbl <- read_csv(\"03_models/post_block9/Table2_post_block9.csv\", show_col_types = FALSE)\n\ntbl |>\n  filter(model == \"m1\", slug %in% c(\"c1_agvhd\", \"c1_rrm\", \"c1_os\", \"c1_nrm\",\n                                      \"c2_agvhd\", \"c2_rrm\", \"c2_os\")) |>\n  mutate(\n    comparison = str_extract(slug, \"^c\\\\d\"),\n    endpoint = str_extract(slug, \"(?<=_).+\"),\n    or_fmt = sprintf(\"%.2f (%.2f–%.2f)\", or_median, ci_low, ci_high)\n  ) |>\n  select(comparison, endpoint, k, or_fmt) |>\n  arrange(comparison, endpoint)\n","language":"r"}}</script></tool-call></div>

<div><tool-result call-id="toolu_011ZsKMuwF2ox4zkAuJMegQj"><script type="application/json">{"version":1,"status":"success","result":{"type":"content","value":[{"type":"text","text":"Output:\n\rindexing Table2_post_block9.csv [================] 755.94MB/s, eta:  0s\r         ...[truncated, total 598 chars]"}]},"resultPreview":{"type":"code","value":"indexing Table2_post_block9.csv [================] 755.94MB/s, eta:  0s\r                                                                       \r# A tibble: 7 × 4\n  comparison endpoint     k or_fmt          \n  <chr>      <chr>    <dbl> <chr>           \n1 c1         agvhd       28 0.67 (0.59–0.78)\n2 c1         nrm         12 0.88 (0.66–1.18)\n3 c1         os          40 0.79 (0.73–0.85)\n4 c1         rrm         38 0.84 (0.76–0.93)\n5 c2         agvhd        9 0.58 (0.44–0.77)\n6 c2         os          10 0.81 (0.74–0.90)\n7 c2         rrm         10 0.79 (0.69–0.89)"},"elapsedMs":115}</script></tool-result></div>



Unfortunately, **relapse incidence was not extracted as a separate endpoint** — only relapse-related mortality (RRM). So we can't directly decompose whether PTCy lowers RRM by reducing relapses or by improving post-relapse survival. But we can draw some informative indirect conclusions:

### The GVL paradox in this data

The combination of results tells a coherent story:

| Endpoint | C1 OR | C2 OR |
|---|---|---|
| aGVHD | 0.67 | 0.58 |
| RRM | 0.84 | 0.79 |
| NRM | 0.88 (ns) | — |
| OS | 0.79 | 0.81 |

PTCy **substantially reduces aGVHD** (33–42% lower odds) while **also reducing relapse-related mortality** (16–21% lower). This is the opposite of what you'd expect if GVL were tightly coupled to GVHD — conventionally, less GVHD should mean less GVL and *more* relapse deaths. Instead, PTCy appears to dissociate GVL from GVHD.

### Confounders to consider

The arm-level characteristics show PTCy arms have median **100% haploidentical donors** (vs. 0% in non-PTCy) and much higher **bone marrow graft use** (23% vs. 2%). These aren't just confounders — they're part of the PTCy platform. The RRM benefit could reflect:

1. **True GVL preservation** — PTCy selectively depletes alloreactive T-cells while sparing tumor-reactive clones
2. **Disease risk differences** — PTCy arms actually had slightly lower high-risk disease (median 51% vs. 57%), which could partly explain lower RRM
3. **Donor/graft biology** — Haploidentical donors with BM grafts may have different relapse biology than MUD/MSD with PBSC

Without relapse incidence data, we can't distinguish between "fewer relapses" and "better survival after relapse." Extracting relapse/progression-free survival or cumulative relapse incidence from these studies would help close that gap.

I'll suggest some questions below.


<span class="suggestion">Extract relapse incidence as an additional endpoint from the source studies to directly test the GVL hypothesis.</span>


<span class="suggestion">Run a meta-regression on RRM with disease_risk_high_pct as a moderator to see if the benefit persists after adjusting for disease risk.</span>


<span class="suggestion">Compare the C3 (MSD-only) subgroup to C1/C2 to see if the RRM benefit disappears when donor type is controlled.</span>





## User

Extract relapse incidence as an additional endpoint from the source studies to directly test the GVL hypothesis.

## Assistant



[An error occurred: Not authenticated with positai]



## User

Run a meta-regression on RRM with disease_risk_high_pct as a moderator to see if the benefit persists after adjusting for disease risk.

## Assistant



[An error occurred: Not authenticated with positai]



## User

Extract relapse incidence as an additional endpoint from the source studies to directly test the GVL hypothesis.

## Assistant



[An error occurred: Not authenticated with positai]



